The clinical success of proteasome inhibitors in hematological malignancies, coupled with the emerging efficacy of Bcl-2 family inhibitors (BH3 mimetics), underscores the therapeutic potential of this combined approach. The gene discussed is BCL2; the disease is hematologic disorder.